No­var­tis rais­es the temp on Eylea ri­val­ry with head-to-head tri­al win for Beovu in di­a­bet­ic mac­u­lar ede­ma

Re­gen­eron’s an­ti-VEGF Eylea has long dom­i­nat­ed its mar­ket, but com­peti­tors are look­ing to de­throne the king — par­tic­u­lar­ly No­var­tis’ late­com­er Beovu. Ham­pered by pri­or safe­ty con­cerns, No­var­tis has set Eylea di­rect­ly in its sights with a pair of non-in­fe­ri­or­i­ty stud­ies for Beovu that could help it get over the line in mac­u­lar ede­ma.

No­var­tis’ Beovu matched Re­gen­eron’s an­ti-VEGF Eylea a year af­ter treat­ment at im­prov­ing di­a­bet­ic mac­u­lar ede­ma pa­tients’ eye­sight in the drug’s sec­ond head-to-head swing at the mar­ket leader, No­var­tis said Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.